Open-label trial of MABP1, a true human monoclonal antibody targeting interleukin 1α, for the treatment of psoriasis

JAMA Dermatology

Volumn 151, Issue 5, 2015, Pages 555-556

  Coleman, Kyle M ^a   Gudjonsson, Johann E ^b   Stecher, Michael ^c  

^a Westlake Dermatology Clinical Research Center Westlake Dermatology and Cosmetic Surgery   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c XBiotech USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MABP1; UNCLASSIFIED DRUG; MABP1 MONOCLONAL ANTIBODY;

BODY SURFACE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; INJECTION SITE REACTION; LETTER; OPEN STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; TREATMENT OUTCOME; ADULT; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HALF LIFE TIME; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1ALPHA; PSORIASIS; TREATMENT OUTCOME;

EID: 84929670705     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.5391     Document Type: Letter

References (5)

1. Mee JB, Cork MJ, Di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006;33(2):72-78.
2. Garrone P, Djossou O, Fossiez F, et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 a specific inhibitor. Mol Immunol. 1996;33(7-8):649-658.
3. Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014;170(4):922-929.
4. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis: CHMP/EWP/2454/02 Corr.. London, England: European Medicines Agency; 2004
5. Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656-666.